Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

National, Multicenter, Randomized, Double-blind, Phase III Clinical Trial to Evaluate the Efficacy and Safety of MAZ-101 in the Treatment of Persistent Allergic Rhinitis (PER)

NCT05684380 is registered in ClinicalTrials.gov with EMS as lead sponsor.

NCT NCT05684380
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05684380 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
National, Multicenter, Randomized, Double-blind, Phase III Clinical Trial to Evaluate the Efficacy and Safety of MAZ-101 in the Treatment of Persistent Allergic Rhinitis (PER)
Lead sponsor
EMS
Phase
Phase 3
Overall status
Unknown status
Start date
September 30, 2024
Completion date
May 31, 2025
Enrollment
514 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

allergic rhinitis